ArticleFrontiers in oncology2020
Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06952400 (T1622 The Registry Study of Genetic Alterations of Melanoma in Taiwan), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
T1622 The Registry Study of Genetic Alterations of Melanoma in Taiwan
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.Clinical & experimental metastasis · 2023Pooled it
- Cutaneous Adverse Reactions and Survival Outcomes of Advanced Melanoma Treated with Immune Checkpoint Inhibitors in an Academic Medical Centre in Singapore.Diagnostics (Basel, Switzerland) · 2024Article
- Comparative transcriptomic analysis reveals differences in gene expression and regulatory pathways between nonacral and acral melanoma in Asian individuals.The Journal of dermatology · 2024Article
- A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients.Journal of the Chinese Medical Association : JCMA · 2023Article
- Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma.Clinical & translational immunology · 2023Article
- Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review.Cancers · 2022Review
- Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab.Current oncology (Toronto, Ont.) · 2022Article
- A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy.Frontiers in immunology · 2021Article
- The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.BMC cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.